SG11202008539YA - Human papillomavirus vaccines and uses of the same - Google Patents

Human papillomavirus vaccines and uses of the same

Info

Publication number
SG11202008539YA
SG11202008539YA SG11202008539YA SG11202008539YA SG11202008539YA SG 11202008539Y A SG11202008539Y A SG 11202008539YA SG 11202008539Y A SG11202008539Y A SG 11202008539YA SG 11202008539Y A SG11202008539Y A SG 11202008539YA SG 11202008539Y A SG11202008539Y A SG 11202008539YA
Authority
SG
Singapore
Prior art keywords
same
human papillomavirus
papillomavirus vaccines
vaccines
human
Prior art date
Application number
SG11202008539YA
Other languages
English (en)
Inventor
Douglas E Brough
Cheryl G Bolinger
Ramya Yarlagadda
Vinodhbabu Kurella
Ponraj Prabakaran
Simon Metenou
Kuan-Fu Ding
Original Assignee
Precigen Inc
Pgen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precigen Inc, Pgen Therapeutics Inc filed Critical Precigen Inc
Publication of SG11202008539YA publication Critical patent/SG11202008539YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/02Hepadnaviridae, e.g. hepatitis B virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20031Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202008539YA 2018-03-06 2019-03-06 Human papillomavirus vaccines and uses of the same SG11202008539YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862639354P 2018-03-06 2018-03-06
PCT/US2019/020933 WO2019173465A1 (fr) 2018-03-06 2019-03-06 Vaccins contre le papillomavirus humain et utilisations de ces derniers

Publications (1)

Publication Number Publication Date
SG11202008539YA true SG11202008539YA (en) 2020-10-29

Family

ID=78414121

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008539YA SG11202008539YA (en) 2018-03-06 2019-03-06 Human papillomavirus vaccines and uses of the same

Country Status (10)

Country Link
US (1) US20210024586A1 (fr)
EP (1) EP3762022A4 (fr)
JP (2) JP2021514667A (fr)
KR (1) KR20200130339A (fr)
CN (1) CN112088015A (fr)
AU (1) AU2019231654A1 (fr)
CA (1) CA3092937A1 (fr)
IL (1) IL277129A (fr)
SG (1) SG11202008539YA (fr)
WO (1) WO2019173465A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3088837A1 (fr) * 2018-01-24 2019-08-01 The Council Of The Queensland Institute Of Medical Research Immunotherapie de l'hpv
EP3762010A4 (fr) 2018-03-06 2022-04-06 Precigen, Inc. Vaccins contre l'hépatite b et utilisations de ces derniers
IL303113A (en) * 2020-11-25 2023-07-01 Precigen Inc Human papillomavirus vaccines and their uses for human papillomavirus-related diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
KR20120118087A (ko) * 2002-12-20 2012-10-25 글락소스미스클라인 바이오로지칼즈 에스.에이. Hpv-16 l1 vlp 및 hpv-18 l1 vlp 백신
EP2371960A3 (fr) * 2005-03-25 2012-01-11 National Research Council of Canada Procédé d'isolation de polypeptides solubles
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
MX362513B (es) * 2010-03-23 2019-01-22 Intrexon Corp Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos.
WO2013112549A1 (fr) * 2012-01-24 2013-08-01 Sanford Research/USD Polynucléotides pour le traitement de tumeurs positives au polypeptide viral oncogène
CN107073070A (zh) * 2014-08-15 2017-08-18 格纳西尼有限公司 治疗宫颈癌的方法
US10596248B2 (en) * 2015-12-09 2020-03-24 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
AU2017272356A1 (en) * 2016-06-03 2018-12-20 Etubics Corporation Compositions and methods for the treatment of human papillomavirus (HPV)-associated diseases

Also Published As

Publication number Publication date
JP2021514667A (ja) 2021-06-17
WO2019173465A1 (fr) 2019-09-12
KR20200130339A (ko) 2020-11-18
US20210024586A1 (en) 2021-01-28
IL277129A (en) 2020-10-29
EP3762022A4 (fr) 2022-06-15
CN112088015A (zh) 2020-12-15
AU2019231654A1 (en) 2020-10-01
CA3092937A1 (fr) 2019-09-12
JP2023138959A (ja) 2023-10-03
EP3762022A1 (fr) 2021-01-13

Similar Documents

Publication Publication Date Title
EP3646883A4 (fr) Nouveau vaccin antitumoral et son utilisation
IL249162A0 (en) Combination therapy of il2 variant tumor-directed immunocytokines and antibodies against human pd-l1
EP3487379A4 (fr) Dispositifs médicaux et procédés d'utilisation
EP3720502A4 (fr) Produits cytobiologiques et leurs utilisations thérapeutiques
EP3758778A4 (fr) Dispositifs médicaux et leurs utilisations
EP3309251A4 (fr) Vecteur viral de parainfluenza de type 2 humain et vaccin
EP3814487A4 (fr) Structure du complexe cgas-adn humain et utilisations associées
IL277129A (en) Human papillomavirus vaccines and their uses
EP3496804A4 (fr) Dispositifs bioélectriques et procédés d'utilisation
EP3411122A4 (fr) Vaccins anticancéreux et méthodes de traitement les utilisant
IL283782A (en) Analosomes and methods of use
EP3727394A4 (fr) Organoïdes humains numérisés et méthodes d'utilisation de ceux-ci
GB201709840D0 (en) Methods and medical uses
IL291180A (en) Bee vaccines and methods of use
EP3765485A4 (fr) Immuno-exosomes et leurs procédés d'utilisation
EP3761989A4 (fr) Imidazodiazépinediones et leurs procédés d'utilisation
EP3703745A4 (fr) Conjugués immunogènes et méthodes d'utilisation de ceux-ci
IL277128A (en) Hepatitis B vaccines and their uses
EP3600398A4 (fr) Vaccins peptidiques pd1 humains et leurs utilisations
EP3684406A4 (fr) Vaccin contre les filovirus et procédés d'utilisation
GB2600270B (en) Polymer-comrprising medical devices and uses thereof
EP3599984A4 (fr) Endoscopes et procédés d'utilisation
IL282142A (en) The history of 4-pyrazine-2-ylmethyl-morpholine and its use as a medicine
EP3897691A4 (fr) Vaccins contenant de l'il-10 et leurs utilisations
EP3836966A4 (fr) Anticorps catalytiques et leurs méthodes d'utilisation